Singh K V, Malathum K, Murray B E
Center for the Study of Emerging and Re-emerging Pathogens, The University of Texas Medical School, Houston, Texas 77030, USA.
Antimicrob Agents Chemother. 2001 Dec;45(12):3640-3. doi: 10.1128/AAC.45.12.3640-3643.2001.
The in vitro activities of ABT-773 were evaluated against 324 strains of gram-positive bacteria, including multidrug-resistant Staphylococcus spp. and Enterococcus spp. ABT-773 had lower MIC ranges, MICs at which 50% of isolates are inhibited (MIC(50)s), and MIC(90)s than erythromycin or clindamycin for almost all isolates tested. The MICs of ABT-773 were also lower than those of quinupristin-dalfopristin (Q-D) for methicillin-susceptible Staphylococcus aureus, Rhodococcus spp., and Streptococcus spp., while the MICs of Q-D were lower than those of ABT-773 for methicillin-resistant S. aureus and Enterococcus faecium, including vancomycin-resistant isolates.
评估了ABT-773对324株革兰氏阳性菌的体外活性，其中包括多重耐药葡萄球菌属和肠球菌属。对于几乎所有测试菌株，ABT-773的最低抑菌浓度（MIC）范围、抑制50%分离株的MIC（MIC50）以及MIC90均低于红霉素或克林霉素。对于甲氧西林敏感金黄色葡萄球菌、红球菌属和链球菌属，ABT-773的MIC也低于奎奴普丁-达福普汀（Q-D），而对于耐甲氧西林金黄色葡萄球菌和粪肠球菌（包括耐万古霉素分离株），Q-D的MIC低于ABT-773。
